Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

89.51 +0.69 (+0.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
51 52 Next >
Snap, Gilead Sciences And Some Other Big Stocks Moving Higher On Monday
Magic Empire Global Limited (NASDAQ: MEGL) shares climbed 80.9% to $14.87 on volatility following the company's IPO earlier this month. 
Via Benzinga
Gilead Shares Climb On Positive Interim Analysis From Late-Stage Breast Cancer Study
Gilead Sciences, Inc. (NASDAQ: GILD) announced positive results from the second interim analysis of the key secondary endpoint of overall survival (OS) in the Phase 3 TROPiCS-02 study evaluating... 
Via Benzinga
Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
From Gilead Sciences, Inc.
Via Business Wire
7 Growth Stocks to Buy After a 20% Correction
These are among the best growth stocks to buy now. ADBE, AMD, GILD, LOW, MELI, MP, and PYPL are poised to benefit from strong trends in 2022. 
Via InvestorPlace
Gilead Sciences Bets $400M On Inflammatory Diseases Focused UK Based Firm
Via Benzinga
Gilead Sciences' Q2 Beats Street View On Robust Oncology, HIV Product Sales
Via Benzinga
Gilead Boosts 2022 Guidance On The Back Of Its Covid Treatment
The company now expects the intravenous drug to generate $2.5 billion in sales this year. 
Via Investor's Business Daily
3 Best Funds for Aggressive Investors
These are the three best funds for aggressive investors. ETFs like BUG, RYT, and BBH can make great investments in the rest of the year. 
Via InvestorPlace
Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency
From Gilead Sciences, Inc.
Via Business Wire
August 2022 Stock Considerations
A look at August stock considerations. 
Via Talk Markets
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Gilead's Biktarvy Demonstrates High Efficacy In HIV/HBV Coinfection Patients
Via Benzinga
Gilead Sciences to Acquire MiroBio
From Gilead Sciences, Inc.
Via Business Wire
Recession Investing: 5 High Yield Dividend Stocks For A Downturn
As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their... 
Via Benzinga
Gilead Sciences: Q2 Earnings Insights
Gilead Sciences (NASDAQ:GILD) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Gilead Sciences beat estimated... 
Via Benzinga
Gilead Sciences Announces Second Quarter 2022 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
European Commission Signs COVID-19 Drug Procurement Deal With Gilead
Via Benzinga
Daily Stock Analysis: Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. 
Via Talk Markets
Australia's Central Bank Has Raised Its Interest Rate. Business Activity In Europe Is Falling
Australia's Central Bank raised its interest rate by 50 basis points to 1.85%. The Bank said in a statement that it attaches great importance to getting inflation back into the 2-3 percent range over... 
Via Talk Markets
Recap Of Thursday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection
From Gilead Sciences, Inc.
Via Business Wire
8 Dividend ETFs to Buy and Hold Forever
Dividend ETFs like these eight provide investors with a steady source of income while they wait for the stock market to recover. 
Via InvestorPlace
Recap Of Friday's Biotech Catalysts - End Of The Day Summary
Via Benzinga
Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
From Gilead Sciences, Inc.
Via Business Wire
CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic
From Gilead Sciences, Inc.
Via Business Wire
7 Best Pharmaceutical Stocks to Buy Now
These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world. 
Via InvestorPlace
Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)
From Gilead Sciences, Inc.
Via Business Wire
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
The group has several commonalities, including strong ratings and promising charts. 
Via Investor's Business Daily
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
51 52 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.